[go: up one dir, main page]

EA201290395A1 - Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций - Google Patents

Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций

Info

Publication number
EA201290395A1
EA201290395A1 EA201290395A EA201290395A EA201290395A1 EA 201290395 A1 EA201290395 A1 EA 201290395A1 EA 201290395 A EA201290395 A EA 201290395A EA 201290395 A EA201290395 A EA 201290395A EA 201290395 A1 EA201290395 A1 EA 201290395A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
relates
cancer
disclosed
sequence
Prior art date
Application number
EA201290395A
Other languages
English (en)
Other versions
EA021867B1 (ru
Inventor
Калет Леон Монсон
Таня Карменате Портилла
Карина Гарсия Мартинес
Агустин Бьенвенидо Лахе Давила
Саумель Перес Родригес
Диамиле Гонсалес Роче
Габриель Маркес Перера
Original Assignee
Сентро Де Инмунологиа Молекулар (Сим)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43646474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290395(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сентро Де Инмунологиа Молекулар (Сим) filed Critical Сентро Де Инмунологиа Молекулар (Сим)
Publication of EA201290395A1 publication Critical patent/EA201290395A1/ru
Publication of EA021867B1 publication Critical patent/EA021867B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение в целом относится к полипептидам, первичная последовательность которых имеет высокую гомологию последовательностей с человеческим интерлейкином 2(IL-2) с некоторыми точечными мутациями в последовательности природного IL-2. Полипептиды согласно изобретению обладают иммуномодулирующим действием на иммунную систему, которое является избирательным/ преимущественным на регуляторных Т-клетках. Также данное изобретение относится к конкретным полипептидам, последовательность аминокислот которых раскрыта в данном описании. В еще одном аспекте представленное изобретение относится к фармацевтическим композициям, содержащим в качестве активного ингредиента раскрытые полипептиды. В заключение, представленное изобретение относится к терапевтическому применению раскрытых полипептидов и фармацевтических композиций благодаря их иммуномодулирующему действию на такие заболевания, как рак и хронические инфекционные заболевания.
EA201290395A 2009-11-27 2010-11-26 Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций EA021867B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20090203A CU23734A1 (es) 2009-11-27 2009-11-27 Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
PCT/CU2010/000005 WO2011063770A2 (es) 2009-11-27 2010-11-26 Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas

Publications (2)

Publication Number Publication Date
EA201290395A1 true EA201290395A1 (ru) 2012-10-30
EA021867B1 EA021867B1 (ru) 2015-09-30

Family

ID=43646474

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290395A EA021867B1 (ru) 2009-11-27 2010-11-26 Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций

Country Status (24)

Country Link
US (1) US8759486B2 (ru)
EP (1) EP2505206B1 (ru)
JP (1) JP5680661B2 (ru)
KR (1) KR101484590B1 (ru)
CN (1) CN102665754B (ru)
AR (1) AR079197A1 (ru)
AU (1) AU2010324254B2 (ru)
BR (1) BR112012012025B8 (ru)
CA (1) CA2781173C (ru)
CL (1) CL2012001030A1 (ru)
CO (1) CO6501124A2 (ru)
CU (1) CU23734A1 (ru)
EA (1) EA021867B1 (ru)
EC (1) ECSP12011803A (ru)
ES (1) ES2643465T3 (ru)
MX (1) MX2012006077A (ru)
MY (1) MY162324A (ru)
NZ (1) NZ599792A (ru)
PE (1) PE20121636A1 (ru)
PH (1) PH12012500812A1 (ru)
SG (1) SG181089A1 (ru)
TN (1) TN2012000182A1 (ru)
WO (1) WO2011063770A2 (ru)
ZA (1) ZA201203762B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2015042707A1 (en) 2013-09-24 2015-04-02 Medicenna Therapeutics Pte Ltd Interleukin-2 fusion proteins and uses thereof
CA2942610C (en) 2014-03-17 2024-02-20 Richard Kroczek Use of a medicament comprising a peptide-loaded peripheral blood mononuclear cell for extending a cellular cytotoxic immune response
US10150802B2 (en) 2014-04-24 2018-12-11 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
KR102708105B1 (ko) 2017-08-03 2024-09-24 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
SG11202004581PA (en) 2017-11-21 2020-06-29 Univ Leland Stanford Junior Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
SG11202009017WA (en) 2018-03-28 2020-10-29 Bristol Myers Squibb Co Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US20210024602A1 (en) * 2018-03-28 2021-01-28 Ascendis Pharma Oncology Division A/S IL-2 Conjugates
WO2019237079A2 (en) * 2018-06-07 2019-12-12 Xiaolong Zhang Pharmaceutical composition containing fusion protein and use thereof
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
US12234271B2 (en) 2019-09-10 2025-02-25 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. METHODS AND COMPOSITIONS OF BIASED IL2 MUTEINS
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CA3191260A1 (en) * 2020-09-04 2022-03-10 Yingying HU Il-2 mutant and application thereof
CA3199447A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
US20240325495A1 (en) 2020-10-29 2024-10-03 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
AU2022267777A1 (en) 2021-04-30 2023-10-05 Centre Hospitalier Universitaire Vaudois (Chuv) Single vessel expansion of lymphocytes
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024097864A1 (en) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
EP1105421A2 (en) 1998-08-21 2001-06-13 Yeda Research & Development Company, Ltd. Anti-inflammatory peptides derived from il-2 and analogues thereof
CA2469151C (en) 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen

Also Published As

Publication number Publication date
KR20120106728A (ko) 2012-09-26
AU2010324254A1 (en) 2012-05-31
WO2011063770A3 (es) 2011-09-09
CO6501124A2 (es) 2012-08-15
CN102665754B (zh) 2014-03-12
NZ599792A (en) 2014-01-31
CL2012001030A1 (es) 2012-07-20
AU2010324254B2 (en) 2014-01-09
ZA201203762B (en) 2013-01-30
JP2013512200A (ja) 2013-04-11
MX2012006077A (es) 2012-09-07
HK1169961A1 (en) 2013-02-15
ECSP12011803A (es) 2012-07-31
EP2505206B1 (en) 2017-09-27
PE20121636A1 (es) 2012-12-03
CU23734A1 (es) 2011-11-15
WO2011063770A2 (es) 2011-06-03
US20120315245A1 (en) 2012-12-13
SG181089A1 (en) 2012-07-30
JP5680661B2 (ja) 2015-03-04
KR101484590B1 (ko) 2015-01-22
CA2781173C (en) 2015-10-13
BR112012012025A2 (pt) 2016-05-17
EA021867B1 (ru) 2015-09-30
PH12012500812A1 (en) 2016-01-27
MY162324A (en) 2017-05-31
CN102665754A (zh) 2012-09-12
BR112012012025B8 (pt) 2021-05-25
ES2643465T3 (es) 2017-11-23
TN2012000182A1 (en) 2013-12-12
CA2781173A1 (en) 2011-06-03
US8759486B2 (en) 2014-06-24
AR079197A1 (es) 2012-01-04
BR112012012025B1 (pt) 2021-05-11
EP2505206A2 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
EA201290395A1 (ru) Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций
EA201390681A1 (ru) Производные полипептиды il-2 с агонистической активностью для лечения рака и хронических инфекций
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
IN2012DN01584A (ru)
UA103221C2 (ru) Стабильный состав рекомбинантного альбумина человека-гранулоцитарного колониестимулирующего фактора человека
UA113729C2 (xx) Мутантний поліпептид інтерлейкіну-2 (il-2)
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
EA201201661A1 (ru) Новые аминопиразолохиназолины
EA201991093A1 (ru) Способ повышения уровней секреции интерлейкина-2 и полученных из него белков
MX2013013913A (es) Polipeptidos.
EA201270572A1 (ru) Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak
MX2013004817A (es) Enfermedad inflamatoria.
WO2018067217A3 (en) COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
WO2012073257A3 (en) Vaccine formulation for prophylaxis and treatment of chandipura virus infections in mammals
UA114298C2 (uk) Пептид торк та вакцина, що його містить
EP4219534A3 (en) Methods for treatment of and prophylaxis against inflammatory disorders
GB2546439A (en) Ezrin-derived peptides and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ